Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H22ClF2N3O |
| Molecular Weight | 393.858 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(CNCC2(F)CCN(CC2)C(=O)C3=CC=C(F)C(Cl)=C3)N=C1
InChI
InChIKey=PKZXLMVXBZICTF-UHFFFAOYSA-N
InChI=1S/C20H22ClF2N3O/c1-14-2-4-16(25-11-14)12-24-13-20(23)6-8-26(9-7-20)19(27)15-3-5-18(22)17(21)10-15/h2-5,10-11,24H,6-9,12-13H2,1H3
Befiradol (also known as NLX-112) was initially developed by Pierre Fabre as a selective serotonin-1A receptor agonist for the treatment of cancer pain and neuropathic pain. However, these trials were discontinued. In 2013, the development and commercialization rights were licensed to Neurolixis. Neurolixis studied befiradol in Parkinson’s disease (PD) patients that exhibit dyskinesia. Dyskinesia is a side effect that appears after several years of action Levodopa, a drug that remains the gold standard treatment for PD. In 2019, FDA gave a positive response to Neurolixis’s befiradol to be tested in Phase 2 clinical in Parkinson's disease patients suffering from debilitating levodopa-induced dyskinesia.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| High-efficacy 5-HT1A receptor activation causes a curative-like action on allodynia in rats with spinal cord injury. | 2004 Aug 16 |
|
| Conformational analysis and crystal structure of {[1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4yl]methyl}[(5-methylpyridin-2-yl)methyl]amine, fumaric acid salt. | 2005 Nov |
|
| Novel pyridylmethylamines as highly selective 5-HT(1A) superagonists. | 2010 Oct 14 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C241
Created by
admin on Fri Dec 15 17:13:27 GMT 2023 , Edited by admin on Fri Dec 15 17:13:27 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9865384
Created by
admin on Fri Dec 15 17:13:27 GMT 2023 , Edited by admin on Fri Dec 15 17:13:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL45305
Created by
admin on Fri Dec 15 17:13:27 GMT 2023 , Edited by admin on Fri Dec 15 17:13:27 GMT 2023
|
PRIMARY | |||
|
208110-64-9
Created by
admin on Fri Dec 15 17:13:27 GMT 2023 , Edited by admin on Fri Dec 15 17:13:27 GMT 2023
|
PRIMARY | |||
|
C81392
Created by
admin on Fri Dec 15 17:13:27 GMT 2023 , Edited by admin on Fri Dec 15 17:13:27 GMT 2023
|
PRIMARY | |||
|
SUB189251
Created by
admin on Fri Dec 15 17:13:27 GMT 2023 , Edited by admin on Fri Dec 15 17:13:27 GMT 2023
|
PRIMARY | |||
|
8953
Created by
admin on Fri Dec 15 17:13:27 GMT 2023 , Edited by admin on Fri Dec 15 17:13:27 GMT 2023
|
PRIMARY | |||
|
100000175063
Created by
admin on Fri Dec 15 17:13:27 GMT 2023 , Edited by admin on Fri Dec 15 17:13:27 GMT 2023
|
PRIMARY | |||
|
DTXSID90943058
Created by
admin on Fri Dec 15 17:13:27 GMT 2023 , Edited by admin on Fri Dec 15 17:13:27 GMT 2023
|
PRIMARY | |||
|
RAT9OHA1YH
Created by
admin on Fri Dec 15 17:13:27 GMT 2023 , Edited by admin on Fri Dec 15 17:13:27 GMT 2023
|
PRIMARY | |||
|
BEFIRADOL
Created by
admin on Fri Dec 15 17:13:27 GMT 2023 , Edited by admin on Fri Dec 15 17:13:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
